Rockville, MD- Innovative Biosensors, Inc. (IBI), a company developing rapid, ultra-sensitive tests to detect harmful pathogens for both the clinical and biodefense markets, today announced the expansion of its Scientific Advisory Board. "We are pleased to announce the addition of Dr. Barry Kreiswirth and Dr. Gary Procop to IBI's diagnostic focused Scientific Advisory Board," said Joe Hernandez, President and CEO. "These individuals are leaders in the field of infectious disease diagnostics and bring essential experience to the Board, which will be critical to our product development efforts in the clinical area". Barry N. Kreiswirth, Ph.D. is Director of the TB Center at the Public Health Research Institute, New York and is a professor of medicine at the University of Medicine and Dentistry of New Jersey. Dr. Kreiswirth earned his Ph.D. in Microbiology from New York University. Two major areas of his research interests include Staphylococcal aureus and Mycobacterium tuberculosis. He has over 70 publications on the biology, molecular epidemiology, and antibiotic resistance of Staph aureus. Dr. Kreiswirth is on the editorial board of several major microbiology journals, and has chaired many prestigious conferences in the area of infectious diseases. Dr. Gary W. Procop, M.D., M.S. is the Chairman of the Department of Clinical Pathology and Director of Molecular Microbiology, Mycology, and Parasitology at the Cleveland Clinic. Dr. Procop earned his MD and MS with major in Microbiology from the Marshall University School of Medicine, WV. He completed Anatomic and Clinical Pathology residency training at Duke University Medical Center and Medical Microbiology fellowship at Mayo Clinic. Dr. Procop has over 150 publications and book chapters. Dr. Procop has participated in a number of clinical trials for diagnostics products and his research interests span a wide spectrum including cancer diagnostics, molecular diagnostics of infectious diseases, and infectious disease pathology. About Innovative Biosensors, Inc. Innovative Biosensors, Inc. is a privately held company developing novel technologies for the rapid detection of pathogens in biodefense applications and human clinical diagnostics.  IBI's technology has been tailored to rapidly and sensitively detect biological threats in building security, military, and civil defense applications.  Additionally, the technology platform is being used to develop rapid tests for the detection of hospital-acquired infections. Additional information is available at www.innovativebiosensors.com. For more information, contact: Joe Hernandez, President and CEO Innovative Biosensors, Inc. Phone: 301.517.0324  Email: info@innovativebiosensors.com Website: www.innovativebiosensors.com This release may contain forward-looking statements that are subject to certain risks and uncertainties, including Innovative Biosensors, Inc.'s mission to develop and commercialize instrument systems, Innovative Biosensors, Inc.'s ability to develop new technologies to conduct rapid diagnosis.  Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.  Innovative Biosensors, Inc. cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: Innovative Biosensors, Inc.'s expectations that they will incur operating losses in the near future, the early stage of preclinical and clinical testing and trials, uncertainties surrounding the availability of additional funding, Innovative Biosensors, Inc.'s reliance on research collaborations, the actions of competitors and the development of competing technologies, potential patent infringement claims against Innovative Biosensors, Inc.'s products, processes and technologies, Innovative Biosensors, Inc.'s ability to protect their patents and proprietary rights and uncertainties relating to commercialization rights.